Crohn Disease-Associated Small Bowel Adenocarcinoma: CT and MRI Findings of a Duodenal Cancer with Liver Metastasis
A radiologic approach to asymmetric bowel-wall thickening, obstruction, lymphadenopathy, and metastatic disease in Crohn disease
Executive Answer
Small bowel adenocarcinoma is an uncommon but clinically important malignancy in patients with Crohn disease. The diagnostic challenge is that its symptoms and imaging appearance can overlap with active inflammation or fibrostenotic Crohn disease. In this case, a man in his late 30s presented with abdominal pain and vomiting. CT demonstrated focal asymmetric duodenal wall thickening with regional lymphadenopathy and a separate low-attenuation liver lesion. MRI demonstrated abnormal bowel-wall thickening and diffusion restriction, with a corresponding abnormal liver lesion. Biopsy established poorly differentiated adenocarcinoma in the duodenum and moderately differentiated adenocarcinoma in the liver, consistent with metastatic small bowel adenocarcinoma. The central imaging lesson is simple: a new, focal, asymmetric, obstructing lesion in a patient with Crohn disease should not automatically be attributed to inflammation.
Why This Case Matters
Crohn disease creates a difficult diagnostic environment for radiologists.
Bowel-wall thickening, mucosal hyperenhancement, strictures, edema, fibrosis, penetrating disease, and mesenteric abnormalities may all be expected findings in Crohn disease. When a patient with established Crohn disease develops abdominal pain or vomiting, an inflammatory stricture or small-bowel obstruction may therefore become the initial diagnostic assumption.
That assumption can become dangerous when the imaging pattern has changed.
Small bowel adenocarcinoma can produce obstruction, abdominal pain, weight loss, gastrointestinal bleeding, and other nonspecific symptoms that overlap substantially with Crohn disease. The tumor may also develop within chronically inflamed bowel, making the distinction between inflammatory stenosis and malignant stenosis particularly difficult.
This case demonstrates why pattern recognition must be combined with longitudinal comparison and whole-abdomen assessment.
The radiologist should not ask only:
"Is there bowel-wall thickening?"
The more useful questions are:
Is the thickening focal or long segmental?
Is it symmetric or asymmetric?
Is the transition abrupt?
Is there an annular mass?
Is the outer bowel contour irregular or nodular?
Are regional lymph nodes enlarged?
Is there a new liver lesion?
Is there peritoneal or other distant disease?
Does the current appearance differ from the patient's previous Crohn disease pattern?
These questions can shift the interpretation from "active Crohn disease" toward "possible malignancy requiring tissue diagnosis."
Clinical Scenario
A man in his late 30s presented with abdominal pain and vomiting.
He had a previous diagnosis of Crohn disease but had been unable to maintain prescribed medical therapy because of financial circumstances.
The clinical differential diagnosis included:
Active Crohn disease
Fibrostenotic Crohn disease
Inflammatory small-bowel obstruction
Abscess
Fistulizing disease
Perforation
Small bowel adenocarcinoma
Malignant bowel obstruction
Metastatic intra-abdominal malignancy
The imaging evaluation became particularly important because the symptoms were not simply chronic, stable manifestations of Crohn disease.
The CT and MRI findings demonstrated a focal asymmetric bowel-wall abnormality involving the duodenum, associated regional lymphadenopathy, and a separate liver lesion.
Subsequent tissue sampling established the diagnosis.
The duodenal lesion showed poorly differentiated adenocarcinoma, while the liver lesion showed moderately differentiated adenocarcinoma.
Together, the imaging and pathology findings support Crohn disease-associated small bowel adenocarcinoma with hepatic metastasis.
Pathophysiology: From Chronic Inflammation to Carcinoma
The biological relationship between chronic Crohn disease and small bowel adenocarcinoma is commonly conceptualized through an inflammation-dysplasia-carcinoma sequence:
Chronic inflammation → repeated mucosal injury and regeneration → dysplasia → adenocarcinoma
Long-standing inflammatory injury creates repeated cycles of epithelial damage and repair. Over time, genetic and molecular abnormalities may accumulate.
The molecular landscape of small bowel adenocarcinoma is heterogeneous. Reported alterations include KRAS, TP53, APC, PIK3CA, SMAD4, and ERBB2, while mismatch repair deficiency and microsatellite instability can also influence tumor biology and therapeutic considerations.
A 2024 pooled genomic analysis of 188 small bowel adenocarcinomas found KRAS and TP53 among the most frequently altered genes, with additional alterations involving APC, PIK3CA, SMAD4, and ERBB2. dMMR was identified in approximately 29.8% of the overall cohort.
This molecular heterogeneity is clinically relevant because modern management increasingly integrates:
Imaging → pathology → molecular profiling → treatment selection
The radiologist contributes the first major component by defining the tumor's location, extent, local invasion, nodal disease, obstruction, and distant metastatic burden.
How Common Is Small Bowel Adenocarcinoma in Crohn Disease?
Small bowel cancer remains uncommon overall.
However, patients with Crohn disease involving the small bowel have an increased relative risk of small bowel cancer. The 2023 ECCO guideline notes approximately a 10-fold increased risk based on meta-analytic evidence, while emphasizing that the absolute risk remains low.
This distinction is important.
A relative increase in risk does not mean that most patients with Crohn disease will develop small bowel cancer. Rather, the increased risk becomes clinically meaningful when the patient's symptoms or imaging pattern become atypical.
ECCO specifically identifies small bowel adenocarcinoma as the most common small-bowel cancer subtype in Crohn disease and notes its predilection for inflamed segments, particularly the distal jejunum and ileum.
Routine imaging or endoscopic surveillance of every Crohn disease patient specifically for small bowel cancer is not currently recommended.
Instead, diagnostic vigilance should increase when clinical or imaging features become suspicious.
Where Does Crohn Disease-Associated Small Bowel Adenocarcinoma Occur?
An important distinction must be made between sporadic small bowel adenocarcinoma and Crohn disease-associated small bowel adenocarcinoma.
Sporadic small bowel adenocarcinoma commonly occurs in the duodenum.
Crohn disease-associated tumors, in contrast, show a stronger association with chronically inflamed small bowel and are particularly associated with the distal jejunum and ileum.
The ileum is therefore an important location to remember when interpreting a Crohn disease patient.
However, this case illustrates why epidemiologic patterns should never override the actual imaging findings.
The tumor in this patient involved the duodenum.
Therefore:
Common location ≠ only location.
A radiologist should interpret the lesion in front of them rather than excluding malignancy simply because its location is less typical for Crohn-associated small bowel adenocarcinoma.
CT Findings: What Should Raise Suspicion?
CT is particularly valuable because it provides a global assessment of the bowel and the abdomen.
The radiologist can evaluate:
Bowel-wall thickness
Enhancement pattern
Luminal narrowing
Obstruction
Adjacent mesentery
Regional lymph nodes
Peritoneal disease
Liver lesions
Other distant abnormalities
Imaging Features That Increase Concern for Small Bowel Adenocarcinoma
| CT Feature | Why It Matters |
|---|---|
| Focal asymmetric wall thickening | Suggests focal neoplastic growth |
| Short-segment stenosis | May favor a tumor over long inflammatory involvement |
| Abrupt shoulder or transition | Can indicate malignant narrowing |
| Annular mass | Characteristic tumor morphology |
| Irregular outer contour | May indicate infiltrative growth |
| Nodular external margin | Raises concern for tumor extension |
| Regional lymphadenopathy | May indicate nodal metastasis |
| Upstream bowel dilation | Indicates clinically significant obstruction |
| Liver lesion | Raises concern for metastatic disease |
| Peritoneal abnormality | May indicate advanced disease |
Do not interpret any of these findings in isolation.
The diagnostic signal becomes stronger when several occur together.
For example:
focal asymmetric thickening + abrupt stenosis + lymphadenopathy + liver lesion
is substantially more concerning than bowel-wall thickening alone.
Figure 1. Axial Contrast-Enhanced Abdominal CT
The axial contrast-enhanced CT demonstrates focal, asymmetric bowel-wall thickening involving the duodenum, accompanied by regional lymphadenopathy. A separate low-attenuation lesion is present in the liver.
Radiologic Interpretation
The combination of focal asymmetric bowel-wall thickening and regional lymphadenopathy should raise concern for a neoplastic process rather than being attributed automatically to active Crohn disease.
The liver lesion adds an important staging consideration because it may represent metastatic disease.
In this case, subsequent biopsy confirmed adenocarcinoma in both sites.
Figure 2. Coronal Contrast-Enhanced CT
The coronal reconstruction demonstrates the longitudinal extent of the duodenal abnormality and helps define the relationship between the stenotic segment and adjacent abdominal structures.
Radiologic Interpretation
Multiplanar CT reconstruction is particularly useful for small-bowel lesions because bowel loops have complex three-dimensional orientations.
A lesion that appears limited on a single axial image may demonstrate a greater longitudinal extent on coronal imaging.
When obstruction is present, assessment should proceed systematically:
Location → length → symmetry → transition → extramural extension → lymph nodes → distant disease
This sequence helps prevent a narrow interpretation focused only on the bowel lumen.
Figure 3. Sagittal Contrast-Enhanced CT
Sagittal reconstruction provides additional information regarding the craniocaudal and anteroposterior extent of the duodenal lesion and its relationship to surrounding structures.
Radiologic Interpretation
No single imaging plane should be considered sufficient for evaluating a complex small-bowel tumor.
Axial, coronal, and sagittal images should be reviewed together to determine:
Exact tumor location
Longitudinal extent
Degree of luminal narrowing
Adjacent organ involvement
Extramural extension
Regional nodal disease
Multiplanar reconstruction is therefore not simply an image-display technique. It is part of the diagnostic reasoning process.
What Does MRI Add?
MRI can provide complementary information in patients with Crohn disease and suspected small bowel malignancy.
In this case, MRI demonstrated abnormal duodenal wall thickening with diffusion restriction. The liver lesion also demonstrated enhancement and diffusion restriction.
Diffusion-weighted imaging (DWI) can increase lesion conspicuity and provide information related to tissue cellularity.
However, one principle is essential:
Diffusion restriction does not equal cancer.
Active inflammation can also demonstrate restricted diffusion.
Therefore, DWI should never be interpreted as an independent cancer detector.
The correct approach is:
Morphology + enhancement + DWI/ADC + clinical course + endoscopy + pathology
The combination is substantially more informative than any individual sequence.
Figure 4. Axial Contrast-Enhanced MRI
Axial contrast-enhanced MRI demonstrates focal asymmetric thickening of the duodenal wall with associated diffusion restriction.
Radiologic Interpretation
The asymmetric morphology is important because active Crohn disease can produce substantial wall thickening and enhancement, but a new focal mass-like or asymmetric abnormality should prompt consideration of malignancy.
DWI increases the conspicuity of the lesion but is not independently diagnostic.
Figure 5. Coronal MRI
Coronal MRI demonstrates the longitudinal extent of the duodenal abnormality. The liver lesion also demonstrates enhancement and diffusion restriction.
Radiologic Interpretation
The combination of an intestinal lesion and a separate liver lesion should immediately trigger a staging-oriented interpretation.
Rather than analyzing the bowel lesion and liver lesion as unrelated abnormalities, the radiologist should ask whether they represent a single disease process.
In this case, pathology established that relationship.
Figure 6. Sagittal MRI
Sagittal MRI provides additional assessment of the spatial extent of the duodenal lesion and its relationship to adjacent abdominal structures.
Radiologic Interpretation
MRI assessment of small bowel malignancy should extend beyond wall thickness.
Important questions include:
What is the longitudinal extent?
Is the lesion asymmetric?
Is there an infiltrative component?
Is there restricted diffusion?
Are regional nodes abnormal?
Are distant lesions present?
This approach converts MRI from a simple bowel-wall measurement tool into a staging and problem-solving examination.
Crohn Disease Stricture vs Small Bowel Adenocarcinoma
This is the central diagnostic challenge.
| Feature | Crohn Disease Inflammation/Fibrosis | Small Bowel Adenocarcinoma |
|---|---|---|
| Distribution | May be multifocal or skip | Often focal |
| Wall thickening | May be symmetric or asymmetric | Often focal and asymmetric |
| Length | Can be long segmental | Often relatively short |
| Luminal narrowing | Variable | May be abrupt and severe |
| Shoulder/abrupt transition | Not typical | Suspicious |
| Mass | Usually absent | May be present |
| Outer contour | Inflammatory changes possible | Irregular/nodular contour may occur |
| Lymph nodes | Reactive enlargement possible | Metastatic nodes possible |
| DWI | Can restrict in active inflammation | Can restrict in tumor |
| Liver lesion | Requires separate evaluation | May represent metastasis |
| Clinical response | May improve with therapy | May progress despite medical treatment |
These are patterns rather than absolute rules.
Crohn disease can produce asymmetric wall thickening, enhancement, obstruction, and enlarged lymph nodes. Conversely, a tumor does not always present as a classic annular mass.
The diagnosis therefore depends on pattern integration, not one isolated imaging feature.
Why Can the Diagnosis Be Missed?
The major diagnostic problem is not that small bowel adenocarcinoma has no imaging manifestations.
The problem is that those manifestations can be embedded within an already abnormal bowel.
1. Anchoring on Crohn Disease
Once Crohn disease is known, new bowel-wall thickening may be automatically attributed to inflammatory activity.
2. Satisfaction of Search
The radiologist identifies active Crohn disease and may stop searching for an additional diagnosis.
3. Failure to Compare Prior Imaging
A newly developed focal lesion may be much more suspicious when compared with previous examinations.
4. Incomplete Evaluation Outside the Bowel
A suspicious bowel lesion should trigger careful evaluation of the liver, peritoneum, lymph nodes, and other abdominal structures.
5. Overreliance on DWI
Restricted diffusion is important but nonspecific.
6. Assuming All Crohn Strictures Are Benign
A persistent or progressively obstructing stricture requires reassessment when the clinical and imaging behavior changes.
The appropriate response is not to blame an individual reader.
Instead, the case highlights a broader workflow vulnerability:
Known chronic disease can become an interpretive anchor.
Differential Diagnosis
When focal small-bowel wall thickening occurs in a patient with Crohn disease, the differential diagnosis may include:
Active Crohn disease
Fibrostenotic Crohn disease
Small bowel adenocarcinoma
Small bowel lymphoma
Gastrointestinal stromal tumor (GIST)
Neuroendocrine tumor
Intestinal tuberculosis
Infectious enteritis
Abscess
Fistulizing disease
Other inflammatory or neoplastic lesions
The imaging pattern can help prioritize these possibilities.
For example, GIST may present as a more exophytic mass, whereas adenocarcinoma more commonly produces luminal narrowing and annular or infiltrative morphology.
Small bowel lymphoma can produce substantial wall thickening but may demonstrate a different pattern of luminal involvement and nodal disease.
Ultimately, when malignancy remains a meaningful possibility, tissue diagnosis is decisive.
Pathology: Connecting Imaging to Diagnosis
Upper gastrointestinal endoscopy with biopsy of the duodenal lesion demonstrated poorly differentiated adenocarcinoma.
Biopsy of the liver lesion demonstrated moderately differentiated adenocarcinoma.
The diagnostic sequence can therefore be represented as:
Crohn disease background à New focal duodenal lesion à Asymmetric wall thickening and obstruction à Regional lymphadenopathy à Liver lesion à Duodenal poorly differentiated adenocarcinoma à Liver moderately differentiated adenocarcinoma à Metastatic small bowel adenocarcinoma
This is the point at which imaging, pathology, and staging become one integrated diagnostic process.
Treatment Considerations
Treatment depends on tumor location, stage, resectability, nodal status, metastatic burden, histology, molecular characteristics, and the patient's overall clinical condition.
For localized small bowel adenocarcinoma, surgical resection with appropriate lymphadenectomy is generally central to treatment.
The surgical strategy depends strongly on tumor location.
For duodenal tumors, the required operation may be substantially different from that used for distal ileal disease. Surgical management therefore requires careful preoperative localization and assessment of adjacent structures.
When metastatic disease is present, management becomes more complex.
Systemic therapy may be considered, and molecular characterization can provide additional information relevant to treatment selection.
Important molecular assessments may include:
Mismatch repair (MMR)
Microsatellite instability (MSI)
KRAS
BRAF
HER2/ERBB2
Other potentially actionable alterations
The 2024 genomic analysis of small bowel adenocarcinoma reinforces the heterogeneity of this disease and the importance of integrating molecular information into modern management.
For the radiologist, the practical message is that staging quality matters.
A report should not simply state that a bowel tumor is present.
It should help answer:
Where is it?
How extensive is it?
Is there obstruction?
Is there local invasion?
Are regional nodes suspicious?
Is there liver metastasis?
Is there peritoneal disease?
What is the overall imaging stage and resectability context?
The AI Perspective: Where Could Medical Imaging AI Help?
This case also illustrates a potential role for AI in radiology—not as an autonomous cancer diagnostician, but as a second-reader and workflow-support system.
A clinically relevant AI workflow could potentially assist with:
Detection of focal bowel-wall abnormalities
Quantitative bowel-wall thickness assessment
Identification of abnormal enhancement patterns
Detection of suspicious lymph nodes
Liver lesion detection
Longitudinal comparison with prior CT or MRI
Structured staging support
Worklist prioritization
Quantitative lesion measurements
However, these applications remain subject to important limitations.
AI may fail when:
Image quality is poor
The lesion is subtle
The abnormality is embedded in severe chronic inflammation
The training population differs from the clinical population
The disease location is unusual
The tumor is not represented adequately in the training dataset
There is a domain shift between institutions
The algorithm generates false-positive findings
A model may also detect an abnormality without correctly determining whether it represents active inflammation, fibrosis, or malignancy.
Therefore:
AI should redistribute diagnostic attention—not replace diagnostic responsibility.
A Practical AI-Enabled Radiology Workflow
A realistic enterprise workflow might look like:
CT/MRI acquisition → PACS → AI orchestration layer → Bowel and liver abnormality detection →Quantitative analysis/comparison with prior examinations → PACS visualization → Radiologist interpretation → RIS report → EHR/EMR → Multidisciplinary clinical decision-making
The most useful AI system would not simply flag "abnormal."
It would ideally provide interpretable information that helps the radiologist answer clinically meaningful questions.
For example:
Is there a new focal bowel abnormality compared with the previous examination?
That question may be more useful than a generic cancer probability score.
Diagnostic Algorithm
This algorithm emphasizes that imaging does not exist independently from pathology and clinical management.
10-Point CT/MRI Checklist
For Crohn disease patients with a new or worsening obstructive presentation, consider documenting:
Is the bowel-wall thickening symmetric or asymmetric?
Is the lesion focal or long segmental?
Is the transition abrupt?
Is there a shoulder or overhanging edge?
Is the external bowel contour nodular?
Is there a discrete mass?
Are regional lymph nodes enlarged or morphologically suspicious?
Is there a new liver lesion?
Is there peritoneal or other distant disease?
Has the appearance changed compared with prior imaging?
When several suspicious findings coexist, the threshold for considering malignancy should become substantially lower.
Featured Snippet Answer
What is the key CT finding of small bowel adenocarcinoma in Crohn disease?
The key CT pattern is a new focal, often asymmetric area of bowel-wall thickening or an annular mass causing luminal narrowing, particularly when associated with abrupt stenosis, irregular outer contour, regional lymphadenopathy, or distant lesions. In a patient with Crohn disease, these findings should not automatically be attributed to inflammatory or fibrotic stricture.
What Is the Most Important Differential Diagnosis?
The most important distinction is between Crohn-related inflammatory/fibrotic stricture and small bowel adenocarcinoma.
Both may cause wall thickening and obstruction. A focal, asymmetric, mass-like lesion with abrupt narrowing, suspicious nodes, or a new distant lesion should increase concern for malignancy.
When Is MRI Useful?
MRI can provide complementary assessment of bowel-wall morphology, enhancement, diffusion characteristics, longitudinal extent, and extraintestinal disease. Diffusion restriction can increase lesion conspicuity, but it is nonspecific because active inflammation may also restrict diffusion.
Practical Radiology Pearls
Pearl 1. Crohn disease does not protect the patient from developing a second pathology.
Pearl 2. A new focal asymmetric stricture deserves a different level of attention than stable chronic inflammatory thickening.
Pearl 3. Regional lymphadenopathy can be an important clue when it accompanies a focal bowel lesion.
Pearl 4. Always evaluate the liver and peritoneum when a suspicious bowel malignancy is identified.
Pearl 5. Diffusion restriction is supportive, not diagnostic, of malignancy.
Pearl 6. Multiplanar CT and MRI review is essential for complex small-bowel lesions.
Pearl 7. Prior examinations can be among the most valuable diagnostic tools.
Pearl 8. The location of a lesion should be interpreted in context; atypical location does not exclude malignancy.
Common Diagnostic Pitfalls
Pitfall 1: "The patient has Crohn disease, so the stricture is inflammatory."
A known diagnosis can become an anchoring point. New morphology should trigger a fresh differential diagnosis.
Pitfall 2: "Restricted diffusion means cancer."
Inflammation can also restrict diffusion. DWI must be interpreted with morphology and clinical context.
Pitfall 3: "There is no large mass, so cancer is unlikely."
Small bowel adenocarcinoma can present primarily as stenosis or focal wall thickening.
Pitfall 4: "The liver lesion is unrelated."
In the appropriate context, a new liver lesion may fundamentally change staging and management.
Pitfall 5: "The lesion is in the duodenum, so it is not Crohn-associated."
Disease distributions describe probabilities, not absolute rules.
FAQ
1. Can Crohn disease cause small bowel adenocarcinoma?
Yes. Patients with Crohn disease involving the small bowel have an increased risk of small bowel cancer, although the absolute risk remains low.
2. What is the most common small bowel adenocarcinoma location in Crohn disease?
Crohn disease-associated small bowel adenocarcinoma has a predilection for inflamed distal jejunum and ileum, particularly the ileum.
3. Can small bowel adenocarcinoma mimic a Crohn stricture?
Yes. Both conditions can cause bowel-wall thickening and luminal narrowing, making differentiation difficult.
4. Does asymmetric wall thickening prove cancer?
No. Asymmetric thickening increases concern but is not pathognomonic.
5. Does diffusion restriction prove malignancy?
No. Active Crohn inflammation can also demonstrate restricted diffusion.
6. Why are regional lymph nodes important?
They may be reactive in Crohn disease, but suspicious regional nodes accompanying a focal tumor-like bowel lesion can raise concern for nodal metastasis.
7. What is the significance of a liver lesion?
In a patient with a suspicious small bowel mass, a new liver lesion may represent metastatic disease and can substantially alter staging and management.
8. Is routine imaging screening for small bowel cancer recommended in all Crohn disease patients?
Current ECCO guidance does not recommend routine imaging or endoscopic surveillance specifically for small bowel cancer in all Crohn disease patients.
9. What is the role of molecular testing?
MMR/MSI and other molecular alterations such as KRAS, BRAF, and HER2/ERBB2 may provide clinically relevant information for treatment planning in appropriate patients.
10. Can AI diagnose small bowel adenocarcinoma?
AI may potentially assist with detection, quantitative assessment, comparison with prior examinations, and workflow prioritization, but it should not replace radiologist interpretation, clinical correlation, or pathology.
Diagnostic Risk Perspective
The most important risk illustrated by this case is diagnostic anchoring.
Crohn disease creates a background of expected abnormalities. When a new abnormality appears, the interpreter may unconsciously incorporate it into the established disease model.
A safer strategy is to ask:
"What is new?"
rather than:
"How does this fit the known Crohn disease?"
This subtle change in question can alter the entire diagnostic process.
The same principle applies to AI-assisted radiology.
An AI system trained primarily to detect inflammatory activity may not reliably distinguish inflammation from an uncommon malignancy unless the model has appropriate training data, validation, and clinical workflow integration.
Therefore, AI should not become a new form of anchoring.
Clinical and Healthcare Workflow Implications
Delayed recognition of small bowel adenocarcinoma may lead to more advanced disease at diagnosis, greater staging complexity, additional procedures, prolonged hospitalization, and more complicated treatment pathways.
The economic implication is therefore qualitative rather than a specific dollar value:
Potentially missed diagnosis → delayed diagnosis → more advanced disease → greater resource utilization
However, AI does not automatically eliminate these costs.
An AI implementation also requires:
Software integration
Infrastructure
Model maintenance
Clinical validation
Radiologist training
Workflow redesign
Monitoring for false positives and false negatives
Management of alert fatigue
Governance and cybersecurity
The value of AI must therefore be evaluated at the system level rather than inferred from model accuracy alone.
Key Takeaways
Small bowel adenocarcinoma is an important but uncommon malignancy associated with Crohn disease.
Crohn-associated tumors preferentially involve chronically inflamed distal jejunum and ileum, but atypical locations such as the duodenum can occur.
A new focal, asymmetric, mass-like or obstructing bowel lesion should not automatically be attributed to Crohn inflammation.
Regional lymphadenopathy and a new liver lesion substantially increase concern for malignancy.
DWI can demonstrate restricted diffusion but cannot independently distinguish cancer from active inflammation.
Multiplanar CT and MRI review improves assessment of tumor extent and relationships.
Pathology remains essential for definitive diagnosis.
MMR/MSI and other molecular findings increasingly contribute to treatment planning.
AI may support detection, comparison, quantification, and workflow prioritization, but human oversight remains essential.
The most important radiologic question is not simply whether bowel-wall thickening exists, but whether its morphology represents a meaningful change from the patient's established Crohn disease pattern.
Medical Disclaimer
This article is provided for medical education and informational purposes only. It is not a substitute for professional medical diagnosis, treatment, or consultation. Individual patients require assessment by qualified healthcare professionals who can integrate clinical history, physical examination, imaging, pathology, and other relevant information.
References
Anzidei M, Napoli A, Zini C, Kirchin MA, Catalano C, Passariello R. Malignant tumours of the small intestine: A review of histopathology, multidetector CT and MRI aspects. British Journal of Radiology. 2011;84(1004):677–690. doi:10.1259/bjr/20673379.
Carchman E. Crohn’s disease and the risk of cancer. Clinics in Colon and Rectal Surgery. 2019;32(4):305–313. doi:10.1055/s-0039-1683923.
Chin YH, Jain SR, Lee MH, et al. Small bowel adenocarcinoma in Crohn’s disease: A systematic review and meta-analysis of the prevalence, manifestation, histopathology, and outcomes. International Journal of Colorectal Disease. 2022;37(1):239–250. doi:10.1007/s00384-021-04050-1.
Guglielmo FF, Anupindi SA, Fletcher JG, et al. Small bowel Crohn disease at CT and MR enterography: Imaging atlas and glossary of terms. RadioGraphics. 2020;40(2):354–375. doi:10.1148/rg.2020190091.
Palascak-Juif V, Bouvier AM, Cosnes J, et al. Small bowel adenocarcinoma in patients with Crohn’s disease compared with small bowel adenocarcinoma de novo. Inflammatory Bowel Diseases. 2005;11(9):828–832. doi:10.1097/01.MIB.0000179211.03650.b6.
Weber NK, Fletcher JG, Fidler JL, et al. Clinical characteristics and imaging features of small bowel adenocarcinomas in Crohn’s disease. Abdominal Imaging. 2015;40:1060–1067. doi:10.1007/s00261-014-0144-7.
Gordon H, Biancone L, Fiorino G, et al. ECCO Guidelines on Inflammatory Bowel Disease and Malignancies. Journal of Crohn’s and Colitis. 2023;17(6):827–854. doi:10.1093/ecco-jcc/jjac187.
Bemelman WA, Warusavitarne J, Sampietro GM, et al. ECCO-ESCP Consensus on Surgery for Crohn’s Disease. Journal of Crohn’s and Colitis. 2018;12(1):1–16. doi:10.1093/ecco-jcc/jjx061.
Faggiani I, D’Amico F, Furfaro F, et al. Small Bowel Cancer in Crohn’s Disease. Cancers. 2024;16(16):2901. doi:10.3390/cancers16162901.
Gelsomino F, Balsano R, De Lorenzo S, Garajová I. Small Bowel Adenocarcinoma: From Molecular Insights to Clinical Management. Current Oncology. 2022;29(2):1223–1236. doi:10.3390/curroncol29020104.
Aparicio T, Henriques J, Svrcek M, et al. Genomic profiling of small bowel adenocarcinoma: A pooled analysis from 3 databases. British Journal of Cancer. 2024;131(1):49–62. doi:10.1038/s41416-024-02687-7.
Comments
Post a Comment